KR20000014188A - Kidney protecting agent composition containing processed ginseng extract - Google Patents

Abstract

The present invention relates to a renal protective agent composition comprising a processed ginseng extract prepared by extracting the processed ginseng obtained by heating a ginseng plant at 110 to 180 ° C. for 0.5 to 20 hours to obtain a nonpolar saponin fraction. It is useful as a therapeutic agent for nephrotoxicity or as an adjuvant of nephrotoxicant.

Description

Kidney protectant composition containing processed ginseng extract

[Industrial use]

The present invention relates to a renal protective agent composition containing a processed ginseng extract as an active ingredient, and more particularly, to extract a non-saponin saponin fraction by extracting the processed ginseng heat-treated at 110 to 180 ℃ for 0.5 to 20 hours It relates to a renal protective agent composition containing as an active ingredient the processed ginseng extract prepared by obtaining a saponin fraction.

[Private Technology]

Kidney is an important excretory organ responsible for urine excretion in the human body. As various medicines and environmental pollutants are toxic to the kidneys, the representative drugs that cause nephrotoxicity are nonsteroidal antipyretic analgesic anti-inflammatory drugs such as phenacetin, aspirin, and indomethacin, puromycin, daunomycin, and cyclophosph Anti-cancer agents such as pamide, penicillamine, adriamycin, cisplatin, immunosuppressive agents, aminoglycoside antibiotics such as amikacin, gentamycin, kanamycin, neomycin, sisomycin, streptomycin, and tobramycin; Cephalosporin antibiotics, carbapenem antibiotics such as imipenem, melopenem, heavy metals such as cadmium, lead, mercury, chromium, and inorganic and organic heavy metal compounds, chloroform, D-serine, sulfonamide, 2-bromoethylene, hydrobromide Compounds such as or fungal toxins such as okaratoxin and citrinin. However, until now, the development of drugs that can effectively prevent or treat nephrotoxicity caused by these nephrotoxic agents has been insufficient.

On the other hand, ginseng is a plant that has been widely used as a representative nourishing tonic since ancient times, and is generally in the form of red ginseng prepared by heat-treating white ginseng or ginseng dried at room temperature, as it is grown and harvested at room temperature. It is used. Many researches on the components and efficacy of ginseng have been reported.The known effects of ginseng are anti-aging, anti-arteriosclerosis and hyperlipidemia, liver function enhancement, radiation disorder removal, immune enhancement, antithrombosis, brain hyperactivity. , Antistress, lowering blood sugar, lowering blood pressure or anticancer effect.

The present inventors have carried out a study on the processing method of ginseng and the changes in its physiological activity and bioactive substances in order to find a means to enhance the efficacy of ginseng by increasing the specific components of ginseng. As a result, it has already been shown that processed ginseng (seon ginseng) heated by ginseng at a high temperature of 110-180 ° C. for 0.5 to 20 hours has superior antioxidant and vasorelaxant effects than conventional ginseng (Korean Patent Application 1995) Year 14973). However, the fact that such processed ginseng can be used as a renal protective agent by reducing the renal toxicity has not been found to date.

As a result of continuous studies on the components and medicinal effects of processed ginseng, the present inventors have found that the non-polar saponin fraction of processed ginseng significantly reduces the renal toxicity caused by a nephrotoxic agent, thereby completing the present invention. Accordingly, an object of the present invention is to provide a novel use as a renal protective agent to reduce the renal toxicity of the processed ginseng extract prepared by extracting the processed ginseng to obtain a non-polar saponin fraction.

1 is a chromatogram showing the results of HPLC analysis of nonpolar saponin fractions obtained from Examples 1 and 2 using a reversed phase column;

2 is a graph showing the results of measuring the function of removing oxygen radicals produced by cisplatin of each fraction obtained from Example 1; And

Figure 3 is a graph showing the effect of the non-polar saponin fraction obtained from Example 1 on the weight loss of rats administered cisplatin.

In order to achieve the above object of the present invention, the present invention is a processed ginseng obtained by heating the ginseng plant at 110 to 180 ℃ for 0.5 to 20 hours as a solvent selected from the group consisting of water, lower alcohols and mixtures thereof. After primary extraction, the organic solvent was removed from the extract and the remaining residue was suspended in water, and then the suspension was secondarily extracted with an organic solvent selected from the group consisting of saturated butanol, ethyl acetate, and mixtures thereof, and organic from the extract. Provided is an elongate protective composition comprising a processed ginseng extract prepared by removing the solvent to obtain a nonpolar saponin fraction as an active ingredient. Panax ginseng, Panax quinquefolium, Panax notoginseng, Panax pseudoginseng or Panax japonicum may be used as the ginseng plant. , The processed ginseng extract may contain at least one compound selected from the group consisting of a compound of Formula 1, a compound of Formula 2 and a compound of Formula 3.

In the present invention, the processed ginseng obtained by heating the ginseng plant at 110 to 180 ° C. for 0.5 to 20 hours is first extracted with a solvent selected from the group consisting of water, lower alcohols and mixtures thereof, and the organic solvent is extracted from the extract. The remaining residue was removed and suspended in water, and then the suspension was second extracted with a nonpolar solvent, the aqueous layer of the extract was taken, and the aqueous layer was selected from the group consisting of saturated butanol, ethyl acetate and mixtures thereof. Provided is a kidney protector composition comprising a processed ginseng extract prepared by tertiary extraction and removing an organic solvent from the extract to obtain a nonpolar saponin fraction as an active ingredient. The ginseng plant may be Panax Ginseng, Panax Quink Polyumium, Panax Notoginseng, Panax Pseudozinseng or Panax Japonicum, and the processed ginseng extract may be a compound of Formula 1, a compound of Formula 2, or a compound of Formula 3 It may contain one or more compounds selected from the group consisting of.

Hereinafter, the present invention will be described in more detail.

In the present invention, to prepare the extract of the processed ginseng used processed ginseng heat-treated for 0.5 to 20 hours at 110 ~ 180 ℃. Ginseng plants that can be used include Panax ginseng, as well as Panax quinfolium, Panax notoginseng, Panax pseudozinseng, or Panax japonicum. This processed ginseng contains a nonpolar saponin component which is not present in the original ginseng or contained in a trace amount, which is newly generated during the heating of the ginseng. In the present invention, the nonpolar saponin fraction is obtained through a series of extraction processes from processed ginseng. That is, first, the processed ginseng obtained by heating the ginseng plant at 110 to 180 ° C. for 0.5 to 20 hours is first extracted with water, a lower alcohol, or a mixed solvent thereof, and the organic solvent is blown from the extract to obtain a residue. The residue is suspended in water and the suspension is extracted secondarily with an organic solvent, wherein an organic solvent may be saturated butanol, ethyl acetate, or a mixed solvent thereof. By removing the organic solvent from the extract thus obtained, a nonpolar saponin fraction can be obtained.

In the case of manufacturing and using processed ginseng from the root of the ginseng plant, the nonpolar saponin fraction may be prepared according to the procedure as described above, but in the case of using the processed ginseng obtained from the leaves or stems of the ginseng plant, There is a need to prevent the mixing of various pigments or other nonpolar components of the stem. That is, the processed ginseng is first extracted with water, a lower alcohol, or a mixed solvent thereof, the organic solvent is blown off, and the residue obtained is suspended in water, followed by an organic solvent such as saturated butanol, ethyl acetate, or a mixed solvent thereof. Before extraction, the non-polar pigment component in the leaf or stem is first removed by second extraction with a non-polar solvent. Hexane, ether, dichloromethane, etc. can be used as a nonpolar solvent. The aqueous layer thus obtained is subjected to tertiary extraction with an organic solvent such as saturated butanol, ethyl acetate or a mixed solvent thereof in the same manner as the root of the ginseng plant.

The nonpolar saponin fraction thus obtained differs slightly depending on the raw materials used, but the compounds of formula 1 (ginsenoside Rg ₃ ) and the compounds of formula 2 (ginsenoside Rg ₅ ) which are rarely present in the raw materials originally used as the main ingredients Or a nonpolar saponin such as a compound of formula 3 (ginsenoside Rk ₁ ). Ginsenoside Rg ₃ has one double bond between carbons at positions 24 and 25, ginsenoside Rg ₅ is located between carbons at positions 20 and 22, and ginsenoside Rk ₁ is located at positions 20 and 21 Each of carbons further has a double bond.

The composition containing the non-polar saponin fraction obtained as described above has an effect of remarkably reducing nephrotoxicity, and thus can be usefully used as a therapeutic agent for nephrotoxicity or as an adjuvant of a drug showing nephrotoxicity. For this purpose, the compositions of the present invention can be administered on their own or in combination with carriers conventionally acceptable in the pharmaceutical art, oral administration of conventional formulations in the pharmaceutical art, for example tablets, capsules, solutions, suspensions and the like. It may be formulated into a variety of preparations, such as for example, injectable solutions or suspensions. In addition, in order to prevent the drug from being degraded by gastric acid during oral administration, an antacid may be used in combination, or a solid oral dosage form such as a tablet may be formulated into a formulation coated with enteric skin.

The dose of the non-polar saponin fraction of the processed ginseng according to the present invention to the human body should be appropriately used depending on the absorption rate, inactivation rate and excretion rate of the active ingredient in the body, the age, sex and condition of the patient, but generally 1 An amount of 50 to 2000 mg, preferably 100 to 500 mg per day is to be administered.

EXAMPLE

Hereinafter, the present invention will be described in more detail with reference to examples showing the constitution and effects of the present invention, which are intended to assist the understanding of the present invention and are not intended to limit the scope of the present invention.

Example 1 Preparation of Processed Ginseng Extract from Ginseng

100 g of ginseng was added to the autoclave and heated at 130 ° C. for 2 hours. The processed ginseng was repeatedly extracted twice with 500 ml of methanol, and then methanol was blown out under reduced pressure to obtain 33 g of methanol extract (total extract). This methanol extract was suspended in 500 ml of water and extracted three times with 300 ml of ethyl acetate to obtain 4 g of ethyl acetate fraction (non-polar saponin fraction). The remaining aqueous layer was extracted three times with 300 ml of saturated butanol to obtain 5 g of butanol fraction (polar saponin fraction). Furthermore, the remaining water layer was concentrated under reduced pressure to obtain 23 g of a water fraction.

Example 2 Preparation of Processed Ginseng Extract from Ginseng Leaves

100 g of ginseng leaves were added to the autoclave and heated at 130 ° C. for 2 hours. The processed ginseng was repeatedly extracted twice with 500 ml of methanol, and then methanol was blown out under reduced pressure to obtain 58 g of methanol extract. The methanol extract was suspended in 500 ml of water and extracted three times with 300 ml of ether to remove the ether extract. Then, the remaining aqueous layer was extracted three times with 300 ml of ethyl acetate to obtain 5 g of ethyl acetate fraction.

Experimental Example 1 Component Analysis of Processed Ginseng

In order to analyze the saponin composition of the ethyl acetate fractions obtained in Examples 1 and 2, a reversed phase column filled with octadecylsilylated silica, acetonitrile and acetonitrile / water / 5% acetic acid solution (25:75:10) The solvent was analyzed by HPLC using a vaporized light scattering detector. The results are shown in FIG.

In FIG. 1, (1) uses the fraction obtained from Example 1, and (2) uses the fraction obtained from Example 2. Peak ① is ginsenoside Rg ₃ (20S), peak ② is ginsenoside Rg ₃ (20R), and peak ③ is 3β, 12β-dihydroxy-damar-20 (21), 24-diene-3-O -β-D-glucopyranosyl- (1 → 2) -β-D-glucopyranoside (3β, 12β-dihydroxy-dammar-20 (21), 24-diene-3-O-β-D-glucopyranosyl -(1 → 2) -β-D-glucopyranoside; ginsenoside Rk ₁ ), peak ④ is ginsenoside Rg ₅ . Therefore, as shown in Figure 1, the ethyl acetate fractions obtained from Examples 1 and 2 contain a large amount of non-polar ginsenosides such as ginsenosides Rg ₃ (20S), Rg ₃ (20R), Rg ₅ , Rk ₁ It can be seen.

Experimental Example 2 Oxygen Radical Removal Ability and Renal Toxicity of Processed Ginseng

In order to evaluate the renal toxicity inhibitory effect of the non-polar saponin fraction of the processed ginseng according to the present invention was used as a representative renal toxicity inducer, cisplatin. First, the ability to remove oxygen radicals produced and secreted by cisplatin stimulation in vitro was measured. In vivo, the samples were administered intraperitoneally in SD rats to determine the degree of inhibition of weight loss, kidney toxicity and hepatotoxicity by cisplatin. Renal toxicity was measured by changes in blood urea nitrogen (BUN) and creatinine levels, and liver toxicity was assayed by measuring s-GOT and s-GPT in serum.

1. Isolation of neutrophils

15 hours after casein was administered to the abdominal cavity of SD rats, the rats were washed with physiological saline containing heparin. The wash solution was centrifuged at 1200 rpm for 7 minutes to remove the supernatant, and 2.0mM Tris-0.14M NH ₄ Cl was added to the precipitated peritoneal cells and left for 30 minutes on ice. Thereafter, the precipitated cells were centrifuged at 1200 rpm for 7 minutes and washed several times with Hanks' balanced salt solution (HBSS) buffer to separate neutrophils.

2. Measurement of oxygen radical scavenging _{^{(O - 2 - radical assay,}} NBT assay)

0.8 ml of nitroblue tetrazolium (NBT; 1 mg / ml) and 0.1 ml of neutrophils (3.8 × 10 ⁷ cells / ml) obtained above were mixed and incubated for 1 minute, followed by 1.8 ml of cisplatin (0.02 mg / ml). The total extract, nonpolar saponin fraction, polar saponin fraction, and water fraction of the processed ginseng obtained in Example 1 were dissolved in HBSS, and 0.2 ml of each was added to make the concentration of the ginseng fraction 0.25mg / ml. At this time, cisplatin (0.02mg / ml) was added to the positive control instead of the ginseng fraction, and physiological saline was added to the negative control. After incubating for about 15 minutes, 1.0 ml of 0.5 M HCl and 0.5 ml of DMSO were added to the precipitate obtained by centrifugation at 2500 rpm for 10 minutes, and then the absorbance was measured at 560 nm to compare the amount of active oxygen.

The results are shown in FIG. In Fig. 2, ① indicates a nonpolar saponin fraction, ② indicates a polar saponin fraction, ③ indicates a water fraction, ④ indicates a total extract, ⑤ indicates a positive control, and ⑥ indicates a negative control result. As shown in Figure 2, the non-polar saponin fraction of processed ginseng removed about 80% of oxygen radicals produced and secreted by neutrophil stimulation of cisplatin at a concentration of 0.25 mg / ml, and the polar saponin fraction at the same concentration. It was shown that 20% was removed, and in particular, the nonpolar saponin fraction of the processed ginseng showed very good oxygen radical removal function.

3. Kidney toxicity inhibitory effect

Five groups of 5 rats, each weighing about 200 grams, were prepared for each group. Nothing was administered to the first group (control), and cisplatin was added to the second, third, fourth, and fifth groups. Intraperitoneally administered at a dose of mg / kg, 29 mg / kg of the non-polar saponin fraction obtained in Example 1 was administered intraperitoneally to the second group 72, 48 and 24 hours prior to cisplatin administration (pre-administration group) Group 3 was administered 24, 48 and 72 hours after cisplatin administration (post-administration group), and group 4 was administered simultaneously with administration of cisplatin (simultaneous administration group), and group 5 was administered only cisplatin. (Cisplatin alone administration group).

3.1 weight change

After administration, the weight change of the experimental animals was observed every day, and the results are shown in FIG. 3. In FIG. 3,-*-is a control group administered nothing,-△-is a cisplatin alone group,-◆-is a pre-administered ethyl acetate fraction obtained in Example 1 72, 48, 24 hours before cisplatin administration Administration group,-■-is a post-administration group administered the ethyl acetate fraction obtained in Example 1 24, 48, 72 hours after the cisplatin administration,-●-is the ethyl acetate fraction obtained in Example 1 simultaneously with the administration of cisplatin The weight change of the co-administration group administered is shown. As shown in Figure 3, the non-polar saponin fraction of processed ginseng was shown to effectively inhibit the weight loss caused by the renal toxicity of cisplatin, especially when administered 24, 48, 72 hours after cisplatin administration It was found to be very effective for the post-administration group.

3.2. Renal Toxicity Indicator

(1) measurement of BUN

BUN (Blood Urea Nitrogen) measurement kit (Yongdong Pharmaceutical Co., Ltd.) was measured using BUN as an indicator of kidney toxicity as described below. 0.1 ml of urease was mixed with 20 ml of buffer, 0.02 ml of enzyme buffer prepared from each experimental animal was added to 0.02 ml of serum and reference solution (urea-N 60 mg / 100 ml), followed by incubation at 37 ° C. for 15 minutes. 2 ml each of the color developing solution was added and incubated at 37 ° C. for 5 minutes. Absorbance was measured at 570 nm to determine the amount of BUN. The results are shown in Table 1.

(2) measurement of creatinine

Using creatinine kit (manufactured by Youngdong Pharmaceutical Co., Ltd.), creatinine, which is an indicator of renal toxicity, was measured as follows. To 0.5 ml of serum isolated from the experimental animals was added 4 ml of a tungustic solution. Then, it was vigorously shaken and left for 10 minutes, followed by centrifugation at 1500 g for 10 minutes. Centrifuged supernatant, creatinine standard solution and 3 ml of distilled water (control), 1 ml of picrate solution and 0.5 ml of 1.4 M NaOH were added sequentially. Then shake well and after exactly 15 minutes, the absorbance was measured at 515 nm. The results are shown in Table 1.

Effect of Nonpolar Saponin Fraction from Processed Ginseng on BUN and Creatinine Concentrations in Rats Treated with Seasplatin BUN (mg / ㎗) Creatinine (mg / dl) Control 20.4 ± 2.4 0.58 ± 0.15 Seasplatin alone group 101.5 ± 2.7 3.64 ± 0.43 Pre-administration group 81.7 ± 2.6 1.52 ± 0.16 Post administration group 17.8 ± 1.2 0.68 ± 0.20

* 4 days after dosing.

It can be seen from Table 1 that the BUN and creatinine levels are completely restored to normal levels in the group (post-administration group) administered with the non-polar saponin fraction obtained in Example 1 after 24, 48, and 72 hours of cisplatin administration.

(3) measurement of sGOT and sGPT

Hepatotoxicity was measured as follows using the GOT and GPT kit (produced by Youngdong Pharmaceutical Co., Ltd.). After 1 ml of GOT and GPT substrate solution was incubated at 37 ° C. for 3 minutes, the mixture was mixed with 0.2 ml of serum separated from the experimental animals, and the culture was incubated for 1 hour and GPT for 30 minutes at 37 ° C. 1 ml of 2,4-dinitrophenylhydrazine (2,4-DNPH) was added thereto, and left at room temperature for 20 minutes. 10 ml of 0.4 M NaOH was added thereto, the mixture was shaken vigorously, and the absorbance was measured at 505 nm. The results are shown in Table 2.

Effect of Non-polar Saponin Fraction from Processed Ginseng on GPT and GOT in Rats Treated with Seasplatin sGPT (Karmen Unit) sGOT (Karmen Unit) Control 24.3 ± 0.6 55.4 ± 2.5 Cisplatin alone 16.5 ± 0.8 42.5 ± 2.9 Pre-administration group 16.2 ± 1.3 44.3 ± 3.5 Post administration group 15.0 ± 0.8 33.2 ± 3.1

* 4 days after dosing.

In Table 2, GOT and GPT, which are indicators of hepatotoxicity, did not deviate from normal values, and thus, the processed ginseng fraction according to the present invention did not have hepatotoxicity, and rather, there was a tendency to decrease these values, indicating a hepatoprotective effect.

As a result, it can be seen that the nonpolar saponin fraction obtained in Example 1 significantly reduces the weight loss, renal toxicity and hepatotoxicity which are side effects caused by cisplatin administration.

Experimental Example 3 Acute Toxicity Test

1. Test Method

The non-polar saponin fraction of the processed ginseng obtained in Example 1 was dissolved in purified water to a concentration of 100, 300 and 500 mg / ml, respectively, to prepare a sample solution for mouse administration. After fasting for 5 hours prior to administration of the sample solution using 6-week-old healthy female and male mice (ICR system), the sample doses were 1000, 3000 and 5000 mg / kg, respectively. The solution was administered orally at 10 ml / kg. Meanwhile, only the same amount of purified water was administered to the control group. In addition, during the test period, the animals were free to feed and water.

All experimental animals were observed for 30 minutes immediately after administration of the sample solution and once a day during the test period. Body weights were measured immediately before and 1, 3, 7 and 14 days after administration. The difference between the control group and the administration group for the weight change was analyzed using Student's t-test.

2. Test result

The results are shown in Table 3.

Number of Dead Animals After Oral Administration of Ginseng Extracts in Mice castle Dose (mg / kg) Days after dosing Final mortality 0 One 2 3 4 5 6 7 8 9 10 11 12 13 14 cock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/5 1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/5 3000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/5 5000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/5 female 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/5 1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/5 3000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/5 5000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0/5

As shown in Table 3, none of the animals died during the test period, indicating that the 50% lethal dose (LD ₅₀ ) of the processed ginseng extract in rats was much higher than 5000 mg / kg. In addition, compared with the control group, the sample administration group did not observe any symptom that was thought to be caused by the administration of the sample, and showed no difference in body weight. Furthermore, no organ abnormalities were observed visually at the time of autopsy after the observation period. In conclusion, the non-polar saponin fraction of the processed ginseng according to the present invention was found to be very safe.

[Composition example]

[Composition Example 1]

34 g of corn starch

40 g of crystalline cellulose

5 g of carboxymethylcellulose calcium

1 g of magnesium stearate

20 g of nonpolar saponin fraction obtained in Example 1

100 g of total

According to the prescription described above, each component was uniformly mixed and then compression molded in a tablet press to prepare 500 mg tablets per tablet. This tablet contains 100 mg of the fraction obtained in Example 1. Adults take 3-10 tablets several times a day.

[Composition Example 2]

39.5 g crystalline cellulose

50 g of 10% hydroxypropylcellulose ethanol solution

5 g of carboxymethylcellulose calcium

0.5 g of magnesium stearate

50 g of nonpolar saponin fractions obtained in Example 1

100 g in total (after drying)

According to the prescription described above, the crystalline cellulose, 10% hydroxypropyl cellulose ethanol solution and the fractions obtained in Example 1 were uniformly mixed, dried and ground using a granulator according to a conventional method, followed by carboxymethylcellulose calcium and magnesium Stearates were mixed and compression molded in a tablet press to prepare 500 mg tablets per tablet. This tablet contains 250 mg of the fraction obtained in Example 1. Adults take 3 to 6 tablets several times a day.

[Composition Example 3]

4.0 g of crystalline cellulose

10 g of magnesium stearate

50 g of nonpolar saponin fractions obtained in Example 1

100 g of total

According to the prescription described above, all the ingredients were uniformly mixed, assembled using a granulator according to a conventional method, and filled in a charger to prepare 500 mg of capsules per capsule. This capsule 1 capsule contains 250 mg of fractions obtained in Example 1. Adults take 3 to 6 capsules several times a day. Adults take 3-6 capsules several times a day.

The processed ginseng extract prepared by extracting the processed ginseng according to the present invention to obtain a non-polar saponin fraction can be used as a therapeutic agent for nephrotoxicity or as an adjuvant of a drug showing nephrotoxicity by having an effect of remarkably reducing nephrotoxicity.

Claims (6)

The processed ginseng obtained by heating the ginseng plant at 110-180 ° C. for 0.5-20 hours was first extracted with a solvent selected from the group consisting of water, lower alcohols and mixtures thereof, and the organic solvent was removed from the extract. Ginseng prepared by suspending the suspension in water, followed by secondary extraction with an organic solvent selected from the group consisting of saturated butanol, ethyl acetate, and mixtures thereof, and removing the organic solvent from the extract to obtain a nonpolar saponin fraction. An kidney protector composition comprising the extract as an active ingredient. The method according to claim 1, wherein the ginseng plant is Panax ginseng, Panax quinquefolium, Panax notoginseng, Panax pseudoginseng and Panax japonicum Elongation protective agent composition is selected from the group consisting of. According to claim 1 or 2, wherein the processed ginseng extract contains one or more compounds selected from the group consisting of a compound of formula (1), a compound of formula (2) and a compound of formula (3). [Formula 1] [Formula 2] [Formula 3] The processed ginseng obtained by heating the ginseng plant at 110-180 ° C. for 0.5-20 hours was first extracted with a solvent selected from the group consisting of water, lower alcohols and mixtures thereof, and the organic solvent was removed from the extract. After the suspension was suspended in water, the suspension was secondly extracted with a nonpolar solvent and the aqueous layer was extracted. The aqueous layer was thirdly extracted with an organic solvent selected from the group consisting of saturated butanol, ethyl acetate and mixtures thereof. An kidney protectant composition comprising as an active ingredient a processed ginseng extract prepared by removing an organic solvent from the extract to obtain a nonpolar saponin fraction. The method according to claim 4, wherein the Ginseng plant is Panax ginseng, Panax quinquefolium, Panax notoginseng, Panax pseudoginseng and Panax japonicum Elongation protective agent composition is selected from the group consisting of. The method according to claim 4 or 5, wherein the processed ginseng extract contains one or more compounds selected from the group consisting of a compound of formula (1), a compound of formula (2) and a compound of formula (3).